You are here / Home / News
 

TSO3: First Quarter 2008 Financial Results

May 8, 2008

Québec City, May 8, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces today the financial results for the first quarter of 2008. The Company recorded a net loss of $2,160,332 or $0.05 per share, compared to a net loss of $2,069,136 or $0.05 per share, for the same period in 2007.

“I am pleased, with the support of the Board, to assume the position of interim President and Chief Executive Officer at TSO3 following the departure of Jocelyn Vézina, and to immediately evaluate and initiate the necessary actions that will lead to enhancing the Company’s revenue and market-share growth”, said W. Barry McDonald, Interim CEO for TSO3 Inc. “In regards to the initiatives to be undertaken in the short term, it is clear that TSO3 must count on a commercialization strategy that is better targeted to our primary market in North America. A realignment of sales and marketing resources to focus on market segmentation will increase our product penetration rate. Based on the strength of the sales record to date and the recent mandate of The Sage Group, we have identified the client profile to target in the very short term, which will allow us to be more effective. We will also look into the Company research and development program to ensure it is well adapted to the needs and expectations of other market segments we are targeting, and segments we wish to develop.”

TSO3 will host a Conference Call at 12:00 P.M. (ET) today, May 8, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montreal area), (416) 915 5763 (Toronto area) or the toll-free number 1-866-250-4892.

Other Interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com. The Webcast will be archived for 90 days.


High Points of the Recent Months

- Mandate to strategic committee composed of board directors and consultants at The Sage Group to re-evaluate the Company’s commercial strategy and ensure that both short-and long-term growth objectives are reached;

- Closing of two very recent sales in the U.S. and re-evaluation of our efforts and resources to increase our sales growth in the coming months;

- Signing of a multi-year agreement with Broadlane, a national group purchasing organization (GPO), serving hundreds of American healthcare organizations;

- Promising preliminary results on the capacity of the 125L Ozone Sterilizer to deactivate prions, the infectious proteins that cause the Creuztfeld-Jakob Disease – the human version of mad cow disease, as part of ongoing research in England.

To view the full announcement, click here.

The full financial results will soon be available in the Investor's section of our Website.
© 2005-2008 TSO3. All Rights Reserved.